PMID- 12876911
OWN - NLM
STAT- MEDLINE
DCOM- 20030911
LR  - 20171116
IS  - 0025-7680 (Print)
IS  - 0025-7680 (Linking)
VI  - 63
IP  - 3
DP  - 2003
TI  - [Role of prostacyclin and its derivatives in the treatment of pulmonary arterial 
      hypertension].
PG  - 233-6
AB  - Pulmonary arterial hypertension (PAH) is defined as a group of diseases 
      characterised by a progressive increase of pulmonary vascular resistance leading 
      to right ventricular failure and death. A dysregulation of prostacyclin metabolic 
      pathways has been demonstrated in patients with PAH and in experimental models. 
      Recently, therapy with continuous intravenous prostacyclin (epoprostenol) has 
      been shown to improve symptoms and prognosis in New York Heart Association (NYHA) 
      functional class III and IV patients with different types of PAH. However, 
      epoprostenol administration requires invasive methods with a permanent 
      intravenous catheter and is associated with several side effects and potentially 
      serious complications. Other modes of prostacyclin therapies are being considered 
      using stable prostacyclin analogues administered by inhalation (iloprost), 
      subcutaneously (treprostinil) or orally (beraprost). Over the last years, 
      different multicenter international double-blind trials have demonstrated the 
      efficacy of those novel prostacyclin analogues in PAH compared to conventional 
      therapy promising a better future for these patients.
FAU - Osvaldo Caneva, Jorge
AU  - Osvaldo Caneva J
AD  - Seccion Neumonologia, Fundacion Favaloro, Av Belgrano 1746, 1093 Buenos Aires, 
      Argentina. jcaneva@ffavaloro.org
FAU - Osses, Juan Manuel
AU  - Osses JM
LA  - spa
PT  - Journal Article
TT  - Rol de la prostaciclina y sus derivados en el tratamiento de la hipertension 
      arterial pulmonar.
PL  - Argentina
TA  - Medicina (B Aires)
JT  - Medicina
JID - 0204271
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Vasodilator Agents)
RN  - 35E3NJJ4O6 (beraprost)
RN  - DCR9Z582X0 (Epoprostenol)
RN  - JED5K35YGL (Iloprost)
RN  - RUM6K67ESG (treprostinil)
SB  - IM
MH  - Antihypertensive Agents/administration & dosage/*therapeutic use
MH  - Epoprostenol/administration & dosage/*analogs & derivatives
MH  - Humans
MH  - Hypertension, Pulmonary/*drug therapy
MH  - Iloprost/administration & dosage
MH  - Vasodilator Agents/administration & dosage/*therapeutic use
EDAT- 2003/07/25 05:00
MHDA- 2003/09/13 05:00
CRDT- 2003/07/25 05:00
PHST- 2003/07/25 05:00 [pubmed]
PHST- 2003/09/13 05:00 [medline]
PHST- 2003/07/25 05:00 [entrez]
PST - ppublish
SO  - Medicina (B Aires). 2003;63(3):233-6.